Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920477 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL17660596 | 0.78 | LMNA (0.33) | ALDH1A1SMN1; SMN2HPGDGFERHSD17B10 | |
| SCHEMBL13091196 | 0.78 | MMP12 (0.44) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL14804002 | 0.72 | HPGD (0.38) | ALDH1A1SMN1; SMN2HPGDGFERHSD17B10 | |
| SCHEMBL9918337 | 0.71 | MMP12 (0.41) | KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21779696 | 0.71 | HPGD (0.37) | KDM4ESMN1; SMN2HPGDGFERHSD17B10 | |
| SCHEMBL12709607 | 0.70 | MEN1 (0.36) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL2705717 | 0.68 | ALOX5 (0.41) | ALDH1A1HPGDGFERHSD17B10LMNA | |
| SCHEMBL5518756 | 0.68 | HPGD (0.33) | ALDH1A1SMN1; SMN2HPGDGFERHSD17B10 | |
| SCHEMBL38657363 | 0.68 | ALOX5 (0.41) | ALDH1A1HPGDGFERHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | KDM4E 449/4885ALDH1A1 1632/4885SMN1; SMN2 3917/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KDM4E 396/4885ALDH1A1 1654/4885SMN1; SMN2 4086/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KDM4E 477/4885ALDH1A1 1507/4885SMN1; SMN2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.